头颈部SABR中基于靶区部位分析定位与分次内精度估算PTV margin
本研究前瞻性收集79例复发或既往照射头颈癌患者共405次SABR治疗分次的数据,比较颅底、颈部/腮腺和黏膜三个亚部位的摆位与定位精度。结果显示颅底部位的分次间和分次内误差显著低于其他部位,最终PTV margin分别为颅底1.5 mm、颈部/腮腺2.0 mm、黏膜1.8 mm,提示头颈SABR的PTV margin应按靶区部位优化。
要点
- 颅底SABR的PTV margin为1.5 mm,颈部/腮腺为2.0 mm,黏膜为1.8 mm
- 使用ExacTrac时颈部/黏膜靶区可能需要加用CBCT以校正摆位误差和器官运动
核心结论
- 头颈SABR的PTV margin应按靶区部位优化,颅底1.5至2 mm可能足够,颈部与黏膜靶区可能需要2至2.5 mm。
- 使用ExacTrac时颅底部位全程不确定性显著更少,颈部/黏膜靶区可能需要加用CBCT以校正摆位误差和器官运动。
研究设计与样本
- 前瞻性研究,纳入79例接受SABR治疗的复发或既往照射头颈癌患者,共405次治疗分次。
- 通过ExacTrac X线对比治疗计划确定分次间误差,复位后重复X线测量残余误差,再将CBCT与ExacTrac对比定位一致性,最后在每个弧前用X线测量分次内误差。
- 结果按治疗部位分层为颅底、颈部/腮腺和黏膜。
主要发现
- 多数患者(66.7%)接受45 Gy分5次治疗(范围21-47.5 Gy分3-5次)。
- 初始分次间平均误差±标准差为前后-0.2±1.4 mm、头脚0.2±1.8 mm、左右-0.1±1.7 mm。
- 所有分次间误差校正至1.3 mm和1.8°以内;CBCT与ExacTrac一致性在3.6 mm和3.4°以内。
关键数值与推荐
- 最终PTV margin:颅底1.5 mm,颈部/腮腺2.0 mm,黏膜1.8 mm。
- 结论推荐颅底PTV margin 1.5至2 mm可能足够,颈部与黏膜靶区可能需要2至2.5 mm。
临床怎么用
- 头颈SABR计划设计时应按靶区部位分别设定PTV margin,颅底可采用较小margin,颈部/腮腺和黏膜靶区需较大margin。
- 使用ExacTrac定位时,颈部/黏膜靶区建议加用CBCT以校正摆位误差和器官运动带来的不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrent or previously irradiated head and neck cancers (HNC) are therapeutically challenging and may benefit from high-dose, highly accurate radiation techniques, such as stereotactic ablative radiation therapy (SABR). Here, we compare set-up and positioning accuracy across HNC subsites to further optimize the treatment process and planning target volume (PTV) margin recommendations for head and neck SABR. METHODS AND MATERIALS: We prospectively collected data on 405 treatment fractions across 79 patients treated with SABR for recurrent/previously irradiated HNC. First, interfractional error was determined by comparing ExacTrac x-ray to the treatment plan. Patients were then shifted and residual error was measured with repeat x-ray. Next, cone beam computed tomography (CBCT) was compared with ExacTrac for positioning agreement, and final shifts were applied. Lastly, intrafractional error was measured with x-ray before each arc. Results were stratified by treatment site into skull base, neck/parotid, and mucosal. RESULTS: Most patients (66.7%) were treated to 45 Gy in 5 fractions (range, 21-47.5 Gy in 3-5 fractions). The initial mean ± standard deviation interfractional errors were -0.2 ± 1.4 mm (anteroposterior), 0.2 ± 1.8 mm (craniocaudal), and -0.1 ± 1.7 mm (left-right). Interfractional 3-dimensional vector error was 2.48 ± 1.44, with skull base significantly lower than other sites (2.22 vs 2.77; P = .0016). All interfractional errors were corrected to within 1.3 mm and 1.8°. CBCT agreed with ExacTrac to within 3.6 mm and 3.4°. CBCT disagreements and intrafractional errors of >1 mm or >1° occurred at significantly lower rates in skull base sites (CBCT: 16.4% vs 50.0% neck, 52.0% mucosal, P < .0001; intrafractional: 22.0% vs 48.7% all others, P < .0001). Final PTVs were 1.5 mm (skull base), 2.0 mm (neck/parotid), and 1.8 mm (mucosal). CONCLUSIONS: Head and neck SABR PTV margins should be optimized by target site. PTV margins of 1.5 to 2 mm may be sufficient in the skull base, whereas 2 to 2.5 mm may be necessary for neck and mucosal targets. When using ExacTrac, skull base sites show significantly fewer uncertainties throughout the treatment process, but neck/mucosal targets may require the addition of CBCT to account for positioning errors and internal organ motion.
引用
- Mesko S, Wang H, Tung S, et al. Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. Int J Radiat Oncol Biol Phys. 2019. PMID: 31580928. doi:10.1016/j.ijrobp.2019.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。